Compare Adaptive Biotechnologies Corp (ADPT) vs American Superconductor Corporation (AMSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs American Superconductor Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while American Superconductor Corporation trades at $32.2 (market cap $1.56B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.6× American Superconductor Corporation's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | AMSC | |
|---|---|---|
Market Cap | $4.04B | $1.56B |
Sector | Health | Technology |
52-Week High | $25.45 | $66.68 |
52-Week Low | $12.30 | $25.95 |
Enterprise Value | $4.10B | $1.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
AMSC trades at $32.28, up 4.16% today, but faces a bearish technical outlook with 14 sell signals versus 3 buys. The company reported strong revenue growth with Q1 2026 sales up 30% to $94.1M (Zacks, Aug 7, 2026) and a record backlog over $400M, though Q2 earnings missed estimates amid margin pressure. Net income margin improved dramatically to 42.56% in 2026 from 2.7% in 2025, but cash flow turned negative with a $60M net outflow in 2026.
The stock presents a mixed opportunity: robust order growth and expanding margins support upside, but high EV/EBITDA (65.73) and technical weakness pose risks. Analyst consensus is bullish (53% Buy), yet investors should watch execution on backlog conversion and margin sustainability amid competitive and cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →
